Compare Deere & Company (DE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Vertex Pharmaceuticals Incorporated — how do they compare? Deere & Company trades at $634.31 (market cap $175.95B), while Vertex Pharmaceuticals Incorporated trades at $510.72 (market cap $127.55B). The key difference: Deere & Company is the larger of the two by market cap, and Deere & Company pays a 0.99% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DE | VRTX | |
|---|---|---|
Market Cap | $175.95B | $127.55B |
Volume | 1,387,231 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $709.48 | $557.96 |
52-Week Low | $439.11 | $407.37 |
Typical Hold Time | 75 Days | 120 Days |
Enterprise Value | $229.85B | $121.68B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $656.87, down 3.8% on the day, showing near-term weakness despite strong earnings beats in recent quarters. The stock maintains a bullish analyst consensus with a $731.20 price target, representing 11% upside potential. Recent financial performance shows declining revenue from $60.2B in 2023 to $44.7B in 2025, though the company continues generating robust operating cash flow exceeding $7B annually. Technical indicators suggest bearish momentum with the stock trading below key resistance levels.
Deere presents a mixed investment case with attractive valuation upside but faces cyclical headwinds in agricultural equipment demand. The company's AI initiatives and dividend payments provide stability, while declining profit margins and elevated debt levels warrant caution. Wall Street remains optimistic with 43% buy ratings, though technical weakness suggests potential near-term pressure before fundamental strength prevails.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
